{
    "ticker": "CABA",
    "name": "Cabaletta Bio, Inc.",
    "description": "Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of autoimmune diseases. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Cabaletta Bio is dedicated to transforming the management of autoimmune conditions by harnessing the power of engineered T cells. The company's lead product candidate, DSG3-CAART, is designed to selectively target and eliminate pathogenic T cells in patients with mucosal pemphigus vulgaris, a severe autoimmune blistering disorder. Cabaletta Bio employs advanced technologies, including its proprietary CABA-Track platform, to enhance the specificity and efficacy of its therapies. The company aims to address significant unmet medical needs in the field of autoimmune diseases, which can have debilitating effects on patients. With a strong commitment to scientific rigor and patient safety, Cabaletta Bio is advancing its clinical programs to bring hope to those affected by challenging autoimmune conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Philadelphia, Pennsylvania, USA",
    "founded": "2018",
    "website": "https://www.cabalettabio.com",
    "ceo": "Michael B. Lichtenstein",
    "social_media": {
        "twitter": "https://twitter.com/CabalettaBio",
        "linkedin": "https://www.linkedin.com/company/cabaletta-bio/"
    },
    "investor_relations": "https://ir.cabalettabio.com",
    "key_executives": [
        {
            "name": "Michael B. Lichtenstein",
            "position": "CEO"
        },
        {
            "name": "Robert M. S. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "DSG3-CAART"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cabaletta Bio, Inc. | Innovative Cell Therapies for Autoimmune Diseases",
        "meta_description": "Explore Cabaletta Bio, Inc., a biotechnology company focused on developing cell therapies for autoimmune diseases. Learn about their lead product candidate and mission.",
        "keywords": [
            "Cabaletta Bio",
            "Biotechnology",
            "Cell Therapy",
            "Autoimmune Diseases",
            "DSG3-CAART"
        ]
    },
    "faq": [
        {
            "question": "What is Cabaletta Bio known for?",
            "answer": "Cabaletta Bio is known for developing innovative cell therapies for autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Cabaletta Bio?",
            "answer": "Michael B. Lichtenstein is the CEO of Cabaletta Bio, Inc."
        },
        {
            "question": "Where is Cabaletta Bio headquartered?",
            "answer": "Cabaletta Bio is headquartered in Philadelphia, Pennsylvania, USA."
        },
        {
            "question": "What is Cabaletta Bio's lead product candidate?",
            "answer": "Cabaletta Bio's lead product candidate is DSG3-CAART."
        },
        {
            "question": "When was Cabaletta Bio founded?",
            "answer": "Cabaletta Bio was founded in 2018."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "ADPT"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "VRTX",
        "GILD"
    ]
}